Patents by Inventor Ervin Horváth

Ervin Horváth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cylopenta[b]benzofuran derivatives and the utilization thereof
    Patent number: 8030347
    Abstract: The present application relates to a novel cyclopenta[b]benzofuran derivatives, processes for their preparation and their use for the manufacture of medicaments, in particular for the prophylaxis and/or therapy of acute or chronic disorders characterized by elevated cellular stress, by local or systemic inflammatory processes or by hyperproliferation.
    Type: Grant
    Filed: May 14, 2005
    Date of Patent: October 4, 2011
    Assignee: Bayer HealthCare AG
    Inventors: Nicole Diedrichs, Thomas Fahrig, Irene Gerlach, Jaques Ragot, Joachim Schuhmacher, Kai Thede, Ervin Horváth
  • Novel Cylopenta[B]Benzofuran Derivatives and the Utilization Thereof
    Publication number: 20090018113
    Abstract: The present application relates to a novel cyclopenta[b]benzofuran derivatives, processes for their preparation and their use for the manufacture of medicaments, in particular for the prophylaxis and/or therapy of acute or chronic disorders characterized by elevated cellular stress, by local or systemic inflammatory processes or by hyperproliferation.
    Type: Application
    Filed: May 14, 2005
    Publication date: January 15, 2009
    Applicant: Bayer HealthCare AG
    Inventors: Nicole Diedrichs, Thomas Fahrig, Irene Gerlach, Jaques Ragot, Joachim Schuhmacher, Kai Thede, Ervin Horvath
  • Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect
    Publication number: 20040186106
    Abstract: The present invention relates to substituted phenylcyclohexanecarboxamides of the formula (I) having adenosine-uptake-inhibiting action, to a process for their preparation and to their use in medicaments, in particular for treating ischaemic brain disorders.
    Type: Application
    Filed: March 18, 2004
    Publication date: September 23, 2004
    Applicant: Bayer Healthcare AG
    Inventors: Wolf-Dietrich Freund, Stephan Lensky, Stephan-Nicholas Muller, Holger Paulsen, Jorg Keldenich, Ervin Horvath, Joachim Schuhmacher
  • Arylsulphonamides and analogues
    Patent number: 6727279
    Abstract: The present invention relates to novel arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: April 27, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jörg Keldenich, Frank Mauler, Jean-Marie-Victor de Vry, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schumacher, Michael-Harold Rock, Ervin Horvàth, Arno Friedl, Klaus-Helmut Mohrs, Siegfried Raddatz, Reinhard Jork
  • Substituted &agr;, &bgr;-anellated butyrolactones
    Patent number: 6723718
    Abstract: The present invention relates to novel substituted &agr;,&bgr;-fused butyrolactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.
    Type: Grant
    Filed: July 25, 2002
    Date of Patent: April 20, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Müller, Jörg Baumgarten, Karsten von dem Bruch, Gerhard Müller, Udo Stropp, Ervin Horváth, Jean-Marie-Viktor de Vry, Rudy Schreiber
  • Substituted phenylcyclohexane carboxylic acid amides that have an adenosine uptake inhibiting effect
    Patent number: 6716849
    Abstract: The present invention relates to substituted phenylcyclohexanecarboxamides of the formula (I) having adenosine-uptake-inhibiting action, to a process for their preparation and to their use in medicaments, in particular for treating ischaemic brain disorders.
    Type: Grant
    Filed: November 29, 2001
    Date of Patent: April 6, 2004
    Assignee: Bayer Aktiengesellschaft
    Inventors: Wolf-Dietrich Freund, Stephan Lensky, Stephan Nicholas Müller, Holger Paulsen, Jörg Keldenich, Ervin Horváth, Joachim Schuhmacher
  • Substituted alpha, beta-anellated butyrolactones
    Publication number: 20030158424
    Abstract: The present invention relates to novel substituted &agr;,&bgr;-fused butyrolactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.
    Type: Application
    Filed: July 25, 2002
    Publication date: August 21, 2003
    Inventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Muller, Jorg Baumgarten, Karsten von dem Bruch, Gerhard Muller, Udo Stropp, Ervin Horvath, Jean-Marie-Viktor de Vry, Rudy Schreiber
  • Aryl sulfonamides and analogues thereof and their use in the treatment of neurodegenerative diseases
    Patent number: 6573278
    Abstract: The present invention relates to new aryl ether sulphonamides and analogues, processes for their preparation and their use for the treatment of neurodegenerative disorders, in particular for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Grant
    Filed: June 11, 2001
    Date of Patent: June 3, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jörg Keldenich, Klaus-Helmut Mohrs, Siegfried Raddatz, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schuhmacher, Michael-Harold Rock, Ervin Horváth, Arno Friedl, Frank Mauler, Jean Marie Viktor de Vry, Reinhard Jork
  • Novel arylsulphonamides and analogues
    Publication number: 20030073727
    Abstract: The present invention relates to novel arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.
    Type: Application
    Filed: August 21, 2002
    Publication date: April 17, 2003
    Inventors: Joachim Mittendorf, Jurgen Dressel, Michael Matzke, Jorg Keldenich, Frank Mauler, Jean-Marie-Victor de Vry, Jurgen Franz, Peter Spreyer, Verena Vohringer, Joachim Schumacher, Michael-Harold Rock, Ervin Horvath, Arno Friedl, Klaus-Helmut Mohrs, Siegfried Raddatz, Reinhard Jork
  • Aryl sulphonamide amino acid esters and analogues
    Patent number: 6545050
    Abstract: The present invention relates to novel amino acid esters of arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: April 8, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jörg Keldenich, Frank Mauler, Jean-Marie-Viktor de Vry, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schumacher, Michael-Harold Rock, Ervin Horvàth, Arno Friedl
  • Use of known agonists of the central cannabinoid receptor CB1
    Patent number: 6525087
    Abstract: The present invention relates to the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Grant
    Filed: May 29, 2001
    Date of Patent: February 25, 2003
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schumacher, Arno Friedl, Ervin Horvath, Frank Mauler, Jean-Marie-Viktor De Vry, Reinhard Jork
  • Use of chromans
    Publication number: 20020177616
    Abstract: The invention relates to the use of 2-[4-({[(2R)-8-isopropoxy-chroman-2-yl]-methyl}amino)butyl]-1,2-benzisothiazol-3(2H)-one 1,1-dioxide, its physiologically acceptable salts, hydrates and/or solvates, in particular its hydrochloride, for the production of a medicament for the prophylaxis and/or treatment of Parkinson's disease.
    Type: Application
    Filed: January 9, 2002
    Publication date: November 28, 2002
    Inventors: Thomas Fahrig, Irene Gerlach, Ervin Horvath, Reinhard Jork, Frank Mauler
  • Aryl sulphonamides and analogues
    Patent number: 6469054
    Abstract: The present invention relates to novel arylsulphonamides and analogues, to processes for their preparation and to their use for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy, craniocerebral trauma, pain and spasticity.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: October 22, 2002
    Assignee: Bayer Aktiengesellshaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jörg Keldenich, Frank Mauler, Jean-Marie-Victor de Vry, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schumacher, Michael-Harold Rock, Ervin Horvàth, Arno Friedl, Klaus-Helmut Mohrs, Siegfried Raddatz, Reinhard Jork
  • Substituted &agr;, &bgr;-anellated butyrolactones
    Patent number: 6462074
    Abstract: The present invention relates to novel substituted (&agr;,&bgr;-fused butyrolactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: October 8, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Müller, Jörg Baumgarten, Karsten von dem Bruch, Gerhard Müller, Udo Stropp, Ervin Horváth, Jean-Marie-Viktor de Vry, Rudy Schreiber
  • Substituted &bgr;,&ggr;-anellated lactones
    Patent number: 6433004
    Abstract: The present invention relates to novel substituted &bgr;,&ggr;-fused lactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, craniocerebral trauma, states of pain or CNS-mediated spasms.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: August 13, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Müller, Jörg Baumgarten, Karsten von dem Bruch, Gerhard Müller, Udo Stropp, Ervin Horváth, Jean-Marie-Viktor de Vry, Rudy Schreiber
  • Arylsulfonamides and analogues
    Publication number: 20020072529
    Abstract: The present invention relates to new aryl ether sulphonamides and analogues, processes for their preparation and their use for the treatment of neurodegenerative disorders, in particular for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Application
    Filed: June 11, 2001
    Publication date: June 13, 2002
    Inventors: Joachim Mittendorf, Jurgen Dressel, Michael Matzke, Jorg Keldenich, Klaus-Helmut Mohrs, Siegfried Raddatz, Jurgen Franz, Peter Spreyer, Verena Vohringer, Joachim Schuhmacher, Michael-Harold Rock, Ervin Horvath, Arno Friedl, Frank Mauler, Jean Marie Viktor de Vry, Reinhard Jork
  • Substituted bicyclic lactones
    Patent number: 6376539
    Abstract: The present invention relates to novel substituted bicyclic lactones, to processes for their preparation and to their use for the prevention and/or treatment of disorders caused by hyper- or hypofunction of the glutamatergic system, in particular of cerebral ischaemias, cranial cerebral trauma, states of pain or CNS-mediated spasms.
    Type: Grant
    Filed: July 14, 2000
    Date of Patent: April 23, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Andreas Stolle, Horst-Peter Antonicek, Stephen Lensky, Arnd Voerste, Thomas Müller, Jörg Baumgarten, Karsten von dem Bruch, Gerhard Müller, Udo Stropp, Ervin Horváth, Jean-Marie-Viktor de Vry, Rudy Schreiber
  • Use of substituted amino-methyl-chromans for the prevention of neuronal degeneration and for the promotion of neuronal regeneration
    Patent number: 6331561
    Abstract: The invention relates to the use of substituted aminomethyl-chromans for the treatment of neuronal degeneration and for the promotion of neuronal regeneration in cerebral injuries and chronic disorders of the nervous system.
    Type: Grant
    Filed: March 9, 2001
    Date of Patent: December 18, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Thomas Fahrig, Irene Gerlach, Ervin Horváth, Reinhard Jork
  • Use of known agonists of the central cannabinoid receptor CB1
    Publication number: 20010034344
    Abstract: The present invention relates to the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Application
    Filed: May 29, 2001
    Publication date: October 25, 2001
    Inventors: Joachim Mittendorf, Jurgen Dressel, Michael Matzke, Jurgen Franz, Peter Spreyer, Verena Vohringer, Joachim Schuhmacher, Arno Friedl, Ervin Horvath, Frank Mauler, Jean-Marie-Viktor De Vry, Reinhard Jork
  • Use of known agonists of the central cannabinoid receptor CB1
    Patent number: 6284788
    Abstract: The present invention relates to the use of known agonists of the central cannabinoid receptor CB1 for the prophylaxis and treatment of neurodegenerative disorders, in particular for the treatment of cerebral apoplexy and craniocerebral trauma.
    Type: Grant
    Filed: February 17, 1998
    Date of Patent: September 4, 2001
    Assignee: Bayer Aktiengesellschaft
    Inventors: Joachim Mittendorf, Jürgen Dressel, Michael Matzke, Jürgen Franz, Peter Spreyer, Verena Vöhringer, Joachim Schuhmacher, Arno Friedl, Ervin Horvath, Frank Mauler, Jean-Marie-Viktor De Vry, Reinhard Jork